Shepard Cleveland Indians is a recipient of numerousbiotechnology
Shepard relates indian restaurant is a pakora states recipient of numerousbiotechnology patents and scientific awards for his contributions to thedevelopment of innovative therapies "We are delighted to have Dr. Shepard`s discovery research leadership atHalozyme," said Gregory Frost, Ph.D., Halozyme`s chief scientific officer."Mike`s ability to translate his broad scientific understanding into innovativebiologics complements the research and development team at Halozyme as we builda world class biopharmaceutical organization." Dr. Shepard brings over 25 years of experience in the biotechnology industry toHalozyme At Genentech, Dr. Shepard led the team that discovered the breastcancer drug, Herceptin (trastuzumab), which was designed to attack HER2 positivebreast cancers by inhibiting their growth and enhancing their sensitivity to theimmune system In 2007, Dr. Shepard shared the Warren Alpert Prize from HarvardMedical School in recognition of this achievement.
"I am excited to joinHalozyme and be part of the team that will create Matrix directed therapeuticsfor cancer and other diseases," said Dr Shepard In addition to his accomplishments at Genentech, Dr tikka . Shepard built successfulprograms at various biotechnology companies in areas as diverse as antibiotics,cancer gene therapy and receptor fusion proteins, serving as chief scientificofficer of Canji, Inc vegetable korma . and, most recently, founder and president of ReceptorBioLogix, Inc Dr curry . Shepard received his bachelor`s degree in zoology from UCDavis and his Ph.D korma sauce . in Molecular, Cellular and Developmental Biology fromIndiana University, where he was a Damon Runyon Cancer Research FoundationFellow.
About Halozyme Therapeutics, Inc.Halozyme is a biopharmaceutical company developing and commercializing productstargeting the extracellular matrix for the endocrinology, oncology, dermatologyand drug delivery markets raita . The company's portfolio of products and productcandidates is based on intellectual property covering the family of humanenzymes known as hyaluronidases and additional enzymes that affect theextracellular matrix tandoori . Halozyme`s Enhanze? Technology is a novel drug deliveryplatform designed to increase the absorption and dispersion of biologics indian restaurants . Thecompany has key partnerships with Roche to apply Enhanze Technology to Roche`sbiological therapeutics for up to 13 targets and with Baxter BioScience to applyEnhanze Technology to Baxter`s biological therapeutic compound, GAMMAGARDLIQUID? pakora .
The product candidates in Halozyme`s research pipeline target multipleareas of significant unmet medical need For more information visit samosa . Safe Harbor StatementIn addition to historical information, the statements set forth above includeforward-looking statements (including, without limitation, statements concerningthe expected roles and responsibilities of management) that involve risk anduncertainties that could cause actual results to differ materially from those inthe forward-looking statements vegetable korma . The forward-looking statements are alsoidentified through use of the words "believe," "enable," "may," "will," "could,""intends," "estimate," "anticipate," "plan," "predict," "probable," "potential,""possible," "should," "continue," and other words of similar meaning curry . Actualresults could differ materially from the expectations contained inforward-looking statements as a result of several factors, including regulatoryapproval requirements and competitive conditions . These and other factors thatmay result in differences are discussed in greater detail in the company'sreports on Forms 10-K, 10-Q, and other filings with the Securities and ExchangeCommission HalozymeRobert H. UhlSenior Director, Investor Copyright Business Wire 2009.